Distribution of hepatitis B virus genotypes in patients with chronic hepatitis B in Turkey

Table 1 Primer sequences used for HBV genotyping by PCR-RFLP.

HBV-1	5’- TCACCATATTCTTgggAACAAgA -3’ (nt 2823-2845, sense)
HBV-2	5’- TTCCTgAACTggAgCCACCA -3’ (nt 80–61, antisense)

Table 2 Baseline characteristics of HBeAg positive and anti-HBe positive patients (mean±SD).

Characteristics	HBeAg positive (n = 33)	Anti-HBe positive(n = 55)	Total(n = 88)
Sex
Male	20	39	59
Female	13	16	29
Age (yr)	28±10	39±9.9	35±11
ALT	113±66	148±107	135±96
AST	69±32	98±90	87±75
GGT	33.6±21.5	49.8±40.6	43.6±35.5
Knodell score	7.5±3.4	7.6±3.2	8.2±3.8

Table 3 ALT and AST values pre-treatment, during and post-treatment (mean±SD).

	ALT	AST
Before treatment	135.0±96.0	87.0±75.0
3rd mo	56.8±20.1	40.6±11.9
6th mo	62.3±38.7	53.3±17.4
6th mo after therapy	43.3±23.0	35.2±19.4

Table 4 Main outcome measurements for patients with CHB treated with interferon-α 2a.

Response outcome		Total	HBeAg positive	Anti-HBe positive	P
Viral response	n	%	%	%
3rd mo	47	53.4	36.3	63.6	<0.01
6th mo	38	43.1	27.2	52.7	<0.05
12th mo	26	29.5	18.1	36.3	>0.1
Biochemical response
3rd mo	30	34.1	21.2	41.8	>0.5
6th mo	26	29.5	24.2	32.7	>0.5
12th mo	25	28.4	24.2	30.9	>0.5
Serological response
3rd mo	4	12.1	12.1	–	–
6th mo	7	21.2	21.2	–	–
12th mo	8	24.2	24.2	–	–

Table 5 Subtype of genotype distribution in patients.

Subtype of genotype	Pre-treatment (n = 78)		Patients who completed the treatment (n = 31)		Non-responder(n = 47)
	n	Percentage	n	Percentage	n	Percentage
- D2	67	85.9	29	93.5	38	80.9
- D2+deletion	7	8.9	2	6.5	5	10.6
- D1	3	3.9	–	–	3	6.4
- D3	1	1.3	–	–	1	2.1